Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data


April 28th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC)

Link:
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Related Posts